Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:BCTNASDAQ:IPANASDAQ:ONCNASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsIPAImmunoPrecise Antibodies$0.96-4.5%$0.57$0.27▼$1.07$45.99M0.112.49 million shs947,526 shsONCBeOne Medicines$257.51+4.2%$245.88$141.31▼$287.88$27.08B0.3301,400 shs450,660 shsTHTarget Hospitality$7.12+0.6%$6.98$4.00▼$11.10$703.50M1.85556,698 shs298,688 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%IPAImmunoPrecise Antibodies0.00%+43.26%+80.40%+133.72%-0.50%ONCBeOne Medicines0.00%-8.36%+2.34%-2.42%+24,707,999,900.00%THTarget Hospitality0.00%+2.91%-3.93%+15.88%-5.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies1.6399 of 5 stars3.53.00.00.00.60.00.6ONCBeOne Medicines1.3393 of 5 stars2.50.00.00.02.21.70.6THTarget Hospitality2.4605 of 5 stars3.41.00.00.02.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTBriaCell Therapeutics 0.00N/AC$15.0041.51% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.00316.62% UpsideONCBeOne Medicines 3.00Buy$319.0023.88% UpsideTHTarget Hospitality 2.75Moderate Buy$11.2558.01% UpsideCurrent Analyst Ratings BreakdownLatest ONC, BCT, IPA, and TH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeOne MedicinesTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/10/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.004/7/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$312.004/7/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$312.004/1/2025IPAImmunoPrecise AntibodiesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AIPAImmunoPrecise Antibodies$18.16M2.42N/AN/A$0.93 per share1.03ONCBeOne Medicines$3.81B7.41N/AN/A$34.10 per share7.55THTarget Hospitality$386.27M1.83$1.49 per share4.77$4.26 per share1.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-190.76%-88.87%-49.26%7/3/2025 (Estimated)ONCBeOne Medicines-$644.79M-$3.72N/A362.69N/A-9.40%-7.55%-4.42%N/ATHTarget Hospitality$71.26M$0.4316.5619.78N/A12.71%11.34%6.94%8/6/2025 (Estimated)Latest ONC, BCT, IPA, and TH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025THTarget Hospitality-$0.02-$0.05-$0.03-$0.07$65.37 million$69.90 million5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion3/28/2025Q3 2025IPAImmunoPrecise Antibodies-$0.06-$0.06N/A-$0.46$6.59 million$4.23 million3/26/2025Q4 2024THTarget Hospitality$0.06$0.12+$0.06$0.12$80.10 million$83.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTBriaCell Therapeutics0.05129.63128.68IPAImmunoPrecise Antibodies0.452.322.11ONCBeOne Medicines0.051.961.71THTarget Hospitality0.101.971.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTBriaCell TherapeuticsN/AIPAImmunoPrecise Antibodies6.70%ONCBeOne Medicines48.55%THTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipBCTBriaCell TherapeuticsN/AIPAImmunoPrecise Antibodies6.83%ONCBeOne Medicines6.62%THTarget Hospitality68.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableIPAImmunoPrecise Antibodies8045.76 million42.64 millionNot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/ATHTarget Hospitality82099.36 million31.80 millionNot OptionableONC, BCT, IPA, and TH HeadlinesRecent News About These CompaniesTarget Hospitality Corp. (NASDAQ:TH) Short Interest Up 23.9% in MayJune 19, 2025 | americanbankingnews.comShort Interest in Target Hospitality Corp. (NASDAQ:TH) Expands By 23.9%June 18, 2025 | marketbeat.com50,000 Shares in Target Hospitality Corp. (NASDAQ:TH) Acquired by Fortitude Advisory Group L.L.C.June 17, 2025 | marketbeat.comTarget Hospitality (NASDAQ:TH) Upgraded by Wall Street Zen to "Hold" RatingJune 15, 2025 | americanbankingnews.comBank of America Corp DE Sells 99,159 Shares of Target Hospitality Corp. (NASDAQ:TH)June 14, 2025 | marketbeat.comTarget Hospitality (NASDAQ:TH) Upgraded at Wall Street ZenJune 14, 2025 | marketbeat.comTwo Sigma Investments LP Has $1.25 Million Holdings in Target Hospitality Corp. (NASDAQ:TH)June 5, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 78,926 Shares of Target Hospitality Corp. (NASDAQ:TH)June 4, 2025 | marketbeat.comTH Q1 Earnings Call: Revenue Miss and Government Contract Shifts Shape 2025 OutlookMay 30, 2025 | msn.comTarget Hospitality (NASDAQ:TH) Lowered to "Sell" Rating by Wall Street ZenMay 26, 2025 | marketbeat.comQ2 EPS Estimate for Target Hospitality Lowered by AnalystMay 24, 2025 | marketbeat.comAnalysts Offer Insights on Industrial Goods Companies: Target Hospitality (TH), Paccar (PCAR) and Carrier Global (CARR)May 22, 2025 | theglobeandmail.comTarget Hospitality Announces Seat on $4 Billion Multi-Year U.S. Government Strategic Sourcing VehicleMay 21, 2025 | prnewswire.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | insidermonkey.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comTarget Hospitality Corp. (TH) Q1 2025 Earnings Call TranscriptMay 19, 2025 | seekingalpha.comTarget Hospitality (NASDAQ:TH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsMay 19, 2025 | msn.comTarget Hospitality (TH) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 19, 2025 | zacks.comTarget Hospitality (TH) Reports Q1 Loss, Tops Revenue EstimatesMay 19, 2025 | zacks.comTarget Hospitality Reports First Quarter 2025 Results with Continued Focus on Pursuing Strong Strategic Growth PipelineMay 19, 2025 | prnewswire.comInsights into Target Hospitality's Upcoming EarningsMay 16, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs3 Stocks Set to Double—And There's Still Time to BuyBy Nathan Reiff | June 12, 2025View 3 Stocks Set to Double—And There's Still Time to BuyNVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s WhyBy Thomas Hughes | May 29, 2025View NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s WhyRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?ONC, BCT, IPA, and TH Company DescriptionsBriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.ImmunoPrecise Antibodies NASDAQ:IPA$0.96 -0.04 (-4.47%) Closing price 04:00 PM EasternExtended Trading$0.95 -0.01 (-1.16%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.BeOne Medicines NASDAQ:ONC$257.51 +10.43 (+4.22%) As of 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Target Hospitality NASDAQ:TH$7.12 +0.04 (+0.56%) Closing price 04:00 PM EasternExtended Trading$7.13 +0.01 (+0.14%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
